6.78k followers • 17 symbols Watchlist by Motif Investing
Successful drug approvals by the FDA and innovations in the treatment of cancer could provide relevant stocks a boost.
Bristol-Myers Squibb Company
Seattle Genetics, Inc.
Exact Sciences Corporation
Blueprint Medicines Corporation
Inovio Pharmaceuticals, Inc.
Spectrum Pharmaceuticals, Inc.
Progenics Pharmaceuticals, Inc.
Merrimack Pharmaceuticals, Inc.
Foundation Medicine, Inc.
INSYS Therapeutics, Inc.
Spectrum Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference 2020
BMS Receives European Commission Approval for Zeposia for Treatment of Adult Patients with Relapsing Remitting Multiple Sclerosis with Active Disease
FDA Approves Opdivo + Yervoy Combined with Limited Chemotherapy as First-Line Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer
Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) for breaches of fiduciary duties and violations of the Securities Exchange Act of 1934. Inovio is a late-stage biotechnology Company that focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines.
Novavax announced it would begin human trials for its coronavirus vaccine, while COVID-19 engulfs Brazil.
Biotech firm Novavax has entered its coronavirus vaccine in a Phase 1 clinical trial in Australia — the first in the Southern Hemisphere.
NEW YORK, May 27, 2020 -- Pomerantz LLP is investigating claims on behalf of investors of Bristol-Myers Squibb Company (“Bristol-Myers” or the “Company”) (NYSE: BMY.RT). Such.
Pharmaceutical company Bristol Myers advanced in 2019 despite shareholder opposition to its Celgene buyout. Now that Bristol has officially acquired Celgene, is it time to buy BMY stock?
MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced plans for a clinical study intended to support registration in the U.S. of flotetuzumab, an investigational, bispecific CD123 x CD3 DART® molecule for patients with acute myeloid leukemia (AML) who are refractory to induction therapy. Informed by recent discussions with the U.S. Food and Drug Administration (FDA), the Company plans a single-arm, registration-enabling clinical study to evaluate flotetuzumab in up to 200 patients with primary induction failure (PIF) or early relapse (ER) AML.
SAN FRANCISCO, May 27, 2020 -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following.
Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Friday, May 29, 2020 to review updated clinical data for pralsetinib in RET-altered cancers. The data will also be presented in the American Society of Clinical Oncology 2020 (ASCO20) Virtual Scientific Program, May 29-31, 2020.
Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conferences and invited investors to participate by webcast.
Vaccines are perceived as key to ending the restraints on work and life that have decimated the global economy, and returning to some sense of normalcy.
Several top health care stocks are in buy zones or setting up, including Teladoc and Neurocrine Biosciences. They are all worth adding to your watchlist.
In the current market session, Geron Inc. (NASDAQ:GERN) is trading at $1.52, after a 22.19% decrease. However, over the past month, the stock increased by 31.47%, and in the past year, by 0.33%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session.Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently under from its 52 week high by 36.46%.The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E indicates that shareholders do not expect the stock to perform better in the future, and that the company is probably undervalued. It shows that shareholders are less than willing to pay a high share price, because they do not expect the company to exhibit growth, in terms of future earnings.Depending on the particular phase of a business cycle, some industries will perform better than others.Compared to the aggregate P/E ratio of the 0.73 in the biotechnology industry, Geron has a lower P/E ratio of 0.0. Shareholders might be inclined to think that they might perform worse than its industry peers. It's also possible that the stock is undervalued.Price to earnings ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors may not be able to attain key insights from trailing earnings.See more from Benzinga * 20 Healthcare Stocks Moving In Friday's Pre-Market Session * Stocks That Hit 52-Week Highs On Monday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The race to develop a vaccine against COVID-19 is charging full speed ahead. Yesterday, Inovio Pharmaceuticals (INO) released promising preclinical data for the biotech’s COVID-19 DNA vaccine candidate, INO-4800. Investors have high hopes for the vaccine maker and have sent the stock soaring by over 332% so far this year. The results, published in Nature Communications, showed INO-4800 elicited strong binding and neutralizing antibody responses in addition to high-level T cell responses in mice and guinea pigs. INO-4800 targets the major antigen spike protein of the SARS-CoV-2 virus, which causes COVID-19, and is currently in a Phase 1 trial. 40 healthy volunteers are taking part, with interim data expected in June. With data in hand, Inovio will approach the FDA for authorization to move forward with a Phase 2/3 trial, which it hopes to initiate in July or August. The company expects to recruit 2,000 frontline healthcare workers for the Phase 2/3 study. “We believe data from this randomized trial, if positive, could allow the company to file for emergency regulatory approval for INO-4800,” said H.C. Wainwright’s Ram Selvaraju. Additionally, Inovio will examine the vaccine in larger animals including rabbits and monkeys. The company will conduct "challenge" studies, which involve giving the virus to an animal and then seeing if the vaccine prevents the infection. “In our view, these animal data bode well for the upcoming data from multiple animal challenge studies and data readout from the ongoing Phase 1 study in June,” Selvaraju added. It should come as no surprise, then, that the 5-star analyst reiterated a Buy rating on Inovio, accompanied by a $17 price target. There’s upside of 22% in the cards, should the target be met over the next 12 months. (To watch Selvaraju’s track record, click here) Over the last three months, 8 analysts have thrown the hat in with a view on the vaccine maker’s prospects, with 5 recommending Buy and 3 saying Hold. This makes the consensus rating a Moderate Buy. Overall, the Street sees upside potential of 18% ahead, as the average price target comes in at $16.57. (See Inovio stock analysis on TipRanks)
Shares of Geron Corp. plunged 26% in premarket trading Friday, after the biopharmaceutical company's large public offering of stock priced at a 34% discount. The stock offering comes about a week after the stock surged to a near 2-year high after the company announced "very encouraging durability data" regarding its cancer treatment imetelstat. On Friday, the company said its offering of 107.05 million common shares priced at $1.30, after the stock closed Thursday at $1.96. The offering represented about 53% of the shares outstanding. The company also offered pre-funded warrants to buy 8.34 million shares, together with warrants to buy 57.69 million shares. The company said it plans to use the proceeds from the offerings to fund its ongoing IMerge Phase 3 trial in lower risk myelodysplastic syndromes to top-line results, its planned Phase 3 clinical trial in refractory myelofibrosis to complete patient enrollment, and for working capital and general corporate purposes. The stock has run up 44.1% year to date through Thursday, while the iShares Nasdaq Biotechnology ETF has gained 9.9% and the S&P 500 has lost 8.7%.
Geron Corporation (GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 107,049,375 shares of its common stock and pre-funded warrants to purchase 8,335,239 shares of common stock, together with accompanying warrants to purchase 57,692,307 shares of common stock. The common stock and pre-funded warrants will be sold in combination with an accompanying warrant to purchase 0.5 of a share of common stock issued for each share of common stock or pre-funded warrant sold.
European Medicines Agency Validates Bristol Myers Squibb’s Applications for Idecabtagene Vicleucel (Ide-cel, bb2121) and CC-486
Geron Corporation (GERN), a late-stage clinical biopharmaceutical company, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock in an underwritten public offering. All of the securities in the proposed offering are to be sold by Geron. A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock and accompanying warrants described above was previously filed with the Securities and Exchange Commission (SEC) and subsequently declared effective by the SEC.